rss
Br J Ophthalmol 2009;93:1047-1051 doi:10.1136/bjo.2008.146910
  • Original Article
  • Clinical Science

Mantle cell lymphoma in the orbital and adnexal region

  1. P Rasmussen1,
  2. L D Sjö1,2,
  3. J U Prause1,
  4. E Ralfkiaer2,
  5. S Heegaard1
  1. 1
    Department of Neuroscience and Pharmacology, Section of Eye Pathology, University of Copenhagen, Denmark
  2. 2
    Department of Pathology, Copenhagen University Hospital, Denmark
  1. Correspondence to Dr S Heegaard, Department of Neuroscience and Pharmacology, Section of Eye Pathology, Frederik V’s Vej 11, 1, DK-2100 Copenhagen, Denmark; sthe{at}sund.ku.dk
  • Accepted 8 April 2009
  • Published Online First 7 May 2009

Abstract

Aims: To characterise clinicopathological features of mantle cell lymphoma (MCL) in the orbital and adnexal region.

Methods: Data on lymphoid lesions were retrieved searching the Danish Ocular Lymphoma Database 1980–2005. Specimens were collected from Danish pathological departments and re-evaluated with a panel of monoclonal antibodies. For all patients with confirmed MCL the complete clinical files were collected and reviewed.

Results: Twenty-one patients with MCL in the orbital and adnexal region were identified comprising 9% (21/230) of all lymphoma in the ocular region. There were 18 male patients and three female patients with an age range from 60 to 90 years (median 75 years). Orbital and adnexal region MCL as first presenting symptom comprised 67% of the patients. Of these, 71% had bilateral involvement. The orbit (71%) and eyelids (64%) were the most commonly affected sites. All but two presented in stage III/IV. Secondary MCL comprised 33% of the patients. Bilateral affection (29%) was less common in this patient group. The median survival was not different between the two presentation groups. Patients receiving anti-CD20 (rituximab)-containing chemotherapy had a significantly better 5-year overall survival (OS) rate (83%) than patients in treatment regimes without rituximab (5-year OS rate, 8%).

Conclusions: Orbital and adnexal region MCL presents in elderly males. The orbit and eyelid are frequently involved. There is a very high proportion of systemic involvement in general with MCL of the orbital and adnexal region. Most patients presented with stage IV disease and had multiple relapses and short survival time. Treatment with rituximab-containing chemotherapy improved survival significantly compared with combination chemotherapy without rituximab.

Footnotes

  • Funding The study was supported by grants from the AP Møller Foundation for the Advancement of Medical Science, The Danish Eye Research Foundation and Øjenforeningen Værn om Synet.

  • Competing interests None.

  • Ethics approval Ethics approval was provided by the Ethics Committee of Copenhagen.

  • Patient consent Obtained.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All versions of this article:
    1. bjo.2008.146910v1
    2. 93/8/1047 most recent

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.